Timber Pharma Shares Jump As Mid-Stage Skin Disorder Study With TMB-001 Concludes Enrollment Early
Timber Pharmaceuticals Inc (NYSE: TMBR) has completed enrollment in the Phase 2b CONTROL study evaluating TMB-001, a topical pharmaceutical composition of isotretinoin, for moderate to severe subtypes of congenital ichthyosis (CI).
